drugset
drugset / Trial / NCT02262520

Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects

NCT02262520 ↗

Phase 1 Completed 24 enrolled Bristol-Myers Squibb Pfizer · collab
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the effects of Apixaban on the Pharmacokinetics (PK) of multiple-dose Digoxin in healthy subjects.

Timeline

Start
2006-01
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule — Oral
Subject Digoxin Other / unclassified — Oral

Indications

No indication recorded.